【摘要】 目的探讨健择(GEM)联合卡铂(CBP)治疗卵巢癌的的疗效和毒副作用。方法24例晚期卵巢癌患者给予GEM 1.2g/m2,静脉滴入,30m in,第1、8天;CBP 400mg/m2,静脉滴入,第1天。每3周为1个周期,2~3个周期后评价疗效和毒副反应。24例可评价疗效患者中,共计62个化疗周期。结果完全缓解(CR)3例,部分缓解(PR)8例,稳定(SD)9例,进展(PD)4例,总有效率(CR+PR)45.8%(11/24)。10例初治患者有效率为60%(6/10),14例复治患者有效率为35.7%(5/14);化疗后白细胞减少发生率为100%,其中Ⅲ~Ⅳ度白细胞下降发生率为29.2%(7/24)。Ⅲ~IV度血小板下降20.8%(5/24),Ⅲ~IV度血红蛋白下降16.7%(4/24)。非血液学毒性较轻。结论GEM联合CBP是治疗卵巢癌疗效较好方案,主要毒性反应为血液学毒性。更多还原

【Abstract】 Objective To investigate the efficacy and toxicity of combined therapy with gemcitabine(GEM) and carboplatin(CBP) in the treatment of ovarian cancer.Methods Twenty-four patients with ovarian cancer received combined chemotherapy of GEM and CBP,GEM 1.2 g/m~2,iv d1,d8;CBP400mg/m~2 iv d1,repeated every 21 days.Assessment was given after 2 or 3 cycles.Results The overall response rate was 45.8 %(11/24),with the complete response(CR) 12.5%(3 cases) and partial response 33.3%(8 cases).The response rate of the 14 relapsed patients was 35.7%(5/14) while those previously untreated patients was 60%(6/10).The main toxicity was hematological toxicity,with 29.2% of patients affected at grade Ⅲ or Ⅳ neutropenia.Conclusion GEM plus CBP is an active and well-tolerated regimen for patients with ovarian cancer.更多还原